Abstract
We report our experience in neoadjuvant breast cancer chemotherapy in a single centre between 2000 and 2011. We looked for predictive factors for response to neoadjuvant chemotherapy in the present study. A total of 110 consecutive breast cancer patients were treated with neoadjuvant chemotherapy in our centre. Pathological response was achieved in 24 HR+/HER2– (38.7%), 25 HER2+ (67.6%) and five triple-negative (45.5%) (p = 0.02) patients. No statistically significant differences were found in pathological tumour response according to T stage. The multivariate analysis revealed tumour subtype was the only associated factor for pathological response, with HER2 + tumours the best responders, OR 3.9 (1.5–9.9): 5-year DFS was 40% HER2+/no response; 78% HER2+/response; 65% HR+/HER2–/no response; 82% HR+/HER2–/response; 25% triple-negative/no response and 100% triple-negative/response. HR and HER2 status were the only prognostic factors for pathological response. pCR was correlated with survival in all tumour subtypes.
Acknowledgements
We thank Kate Williams for her help in writing the manuscript and revision of English.
Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.